

National Plasma Product Expert Advisory Group (NPPEAG)

Gyle Square
1 South Gyle Crescent
Edinburgh EH12 9EB
Telephone 0131 275 6575
Fax 0131 275 7614
www.nsd.scot.nhs.uk



NHS Board Medical Directors
NHS Board Directors of Pharmacy

Date 14 March 2019
Your ref
Our ref 09 NSD\Ctees & Grps\Policy Grps\NPPEAG-
Plasma\Corres\2019\
2019-03-14 Ltr Various - Clinical Tetanus
Telephone 0141 211 4237
Enquiries to Dr Rachel Green
Email Rachelgreen2@nhs.net

Dear Colleague

Management and Treatment of Clinical Tetanus and Tetanus Prone Wounds

This letter is to make you aware of a number of changes to the tetanus guidance that is now available on the following link:

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/754976/Tetanus_information_for_health_professionals.pdf

These revised guidelines amalgamate previous guidelines and provide updated advice on treatment of suspected tetanus cases and management of tetanus prone wounds and replace all previous guidelines in this area

I would like to draw your attention to the advice for the management of clinical tetanus. Previously a national stockholding was available from one site in Scotland to treat those with suspected disease. A number of intravenous preparations of immunoglobulins have been tested and found to have sufficient antibody levels to treat patients. These immunoglobulins, named in the document, form part of the range of immunoglobulins that hospital pharmacy departments will stock, and the national stock holding will be withdrawn going forward.

Please cascade this message to A&E Departments and Primary Care.

Yours sincerely

A handwritten signature in black ink that reads 'Rachel HA Green'.

Dr Rachel Green
Chair, NPPEAG
Chief of Medicine
Diagnostics Directorate
Acute Services Division
NHS GG&C